Journal
PROSTAGLANDINS & OTHER LIPID MEDIATORS
Volume 82, Issue 1-4, Pages 135-146Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.prostaglandins.2006.05.022
Keywords
15-lipoxygenase 2; prostate epithelial cells; prostate cancer; cell senescence; stem cells; differentiation; cell growth
Categories
Funding
- NCI NIH HHS [CA90297] Funding Source: Medline
- NIA NIH HHS [AG023374] Funding Source: Medline
- NIEHS NIH HHS [P50 ES07784] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA090297] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [R01AG023374] Funding Source: NIH RePORTER
Ask authors/readers for more resources
15-Lipoxygenase 2 (15-LOX2) is the major mammalian lipoxygenase expressed in normal human adult prostate and its expression is decreased or lost in high-grade prostate intraepithelial neoplasia (HGPIN) and prostate cancer (PCa). Our recent work has demonstrated that (1) 15-LOX2 has multiple alternatively spliced isoforms and is a negative cell-cycle regulator in normal human prostate (NHP) epithelial cells; (2) 15-LOX2 in NHP cells is positively regulated by Sp1 and negatively regulated by Spa; (3) 15-LOX2 in NHP cells may be partially involved in cell differentiation; (4) 15-LOX2 is cell-autonomously upregulated in cultured NHP cells and its induction is associated with NHP cell senescence; and (5) 15-LOX2 is a functional prostate tumor suppressor. Here we summarize these new findings to provide a concise view of the potential biological functions of 15-LOX2 in NHP cells and of its deregulation in PCa development. (c) 2006 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available